What Caliway’s CBL-514 and tirzepatide combination data could reveal about obesity treatment next
Caliway’s CBL-514 heads to ADA 2026 with tirzepatide combination data. Read what this could change in obesity treatment strategy.
Pharma & Biotech
Pharma & Biotech
How Orum Therapeutics plans to solve GSPT1 toxicity with a DAC approach in AML
Orum Therapeutics presents ORM-1153 DAC preclinical data at AACR 2026, including primate safety findings ahead of a planned AML IND filing. Read the analysis.
Pharma & Biotech
Can CRISPR editing of NRF2 reverse resistance in head and neck squamous cell carcinoma?
CorriXR’s new data show CRISPR-based NRF2 disruption restores chemo response in squamous tumors. Find out what this could mean for HNSCC treatment.
Pharma & Biotech
Can TN-001 avoid hallucinogenic pitfalls while delivering rapid antidepressant effects?
Transneural’s TN-001 shows rapid neuroplasticity without hallucinogenic effects. Find out what this could mean for MDD and PTSD treatment strategies.